Abstract:Background: Perfluorohexane sulfonate (PFHxS) is a frequently detected per- and polyfluoroalkyl substance in most populations, including in individuals who are pregnant, a period critical for early life development. Despite epidemiological evidence of exposure, developmental toxicity, particularly at realistic human exposures, remains understudied. Objectives: We evaluated the effect of gestational exposure to human-relevant body burden of PFHxS on fetal and placental development and explored mechanisms of action combining alternative splicing (AS) and gene expression (GE) analyses. Methods: Pregnant ICR mice were exposed to 0, 0.03, and 0.3 mu g / kg / day from gestational day 7 to day 17 via oral gavage. Upon euthanasia, PFHxS distribution was measured using liquid chromatography-tandem mass spectrometry. Maternal and fetal phenotypes were recorded, and histopathology was examined for placenta impairment. Multiomics was adopted by combining AS and GE analyses to unveil disruptions in mRNA quality and quantity. The key metabolite transporters were validated by quantitative real-time PCR (qRT-PCR) for quantification and three-dimensional (3D) structural simulation by AlphaFold2. Targeted metabolomics based on liquid chromatography-tandem mass spectrometry was used to detect amino acid and amides levels in the placenta. Results: Pups developmentally exposed to PFHxS exhibited signs of intrauterine growth restriction (IUGR), characterized by smaller fetal weight and body length (p < 0.01 ) compared to control mice. PFHxS concentration in maternal plasma was 5.01 +/- 0.54 ng / mL . PFHxS trans-placenta distribution suggested dose-dependent transfer through placental barrier. Histopathology of placenta of exposed dams showed placental dysplasia, manifested with an attenuated labyrinthine layer area and deescalated blood sinus counts and placental vascular development index marker CD34. Combined GE and AS analyses pinpointed differences in genes associated with key biological processes of placental development, proliferation, metabolism, and transport in placenta of exposed dams compared to that of control dams. Further detection of placental key transporter gene expression, protein structure simulation, and amino acid and amide metabolites levels suggested that PFHxS exposure during pregnancy led to impairment of placental amino acid transportation. Discussion: The findings from this study suggest that exposure to human-relevant very-low-dose PFHxS during pregnancy in mice caused IUGR, likely via downregulating of placental amino acid transporters, thereby impairing placental amino acid transportation, resulting in impairment of placental development. Our findings confirm epidemiological findings and call for future attention on the health risk of this persistent yet ubiquitous chemical in the early developmental stage and provide a new approach for understanding gene expression from both quantitative and qualitative omics approaches in toxicological studies.

Maternal F-53B exposure during pregnancy and lactation induced glucolipid metabolism disorders and adverse pregnancy outcomes by disturbing gut microbiota in mice

Gestational Exposure to Ambient Fine Particulate Matter Disrupts Maternal Hepatic Lipid Metabolism.

Placental Inflammatory Injury Induced by Chlorinated Polyfluorinated Ether Sulfonate (F-53B) Through NLRP3 Inflammasome Activation

Maternal F-53B Exposure During Pregnancy and Lactation Affects Bone Growth and Development in Male Offspring

Gestational Exposure to Bisphenol AF Causes Endocrine Disorder of Corpus Luteum by Altering Ovarian SIRT-1/Nrf2/NF-kB Expressions and Macrophage Proangiogenic Function in Mice.

Hepatic injury and ileitis associated with gut microbiota dysbiosis in mice upon F–53B exposure

Chronic Exposure to 6:2 Chlorinated Polyfluorinated Ether Sulfonate Acid (F-53B) Induced Hepatotoxic Effects in Adult Zebrafish and Disrupted the PPAR Signaling Pathway in Their Offspring.

Maternal Exposure to Tributyltin During Early Gestation Increases Adverse Pregnancy Outcomes by Impairing Placental Development

Multi-omics reveal disturbance of glucose homeostasis in pregnant rats exposed to short-chain perfluorobutanesulfonic acid

Maternal PFOS Exposure in Mice Induces Hepatic Lipid Accumulation and Inflammation in Adult Female Offspring: Involvement of Microbiome-Gut-liver Axis and Autophagy

Evaluating the Effect of Gestational Exposure to Perfluorohexane Sulfonate on Placental Development in Mice Combining Alternative Splicing and Gene Expression Analyses

Contribution of gut microbiota to hepatic steatosis following F-53B exposure from the perspective of glucose and fatty acid metabolism

Differential impact of perfluorooctanoic acid and fluorotelomer ethoxylates on placental metabolism in mice

Two-generational Reproductive Toxicity Assessment of 6:2 Chlorinated Polyfluorinated Ether Sulfonate (F-53B, a Novel Alternative to Perfluorooctane Sulfonate) in Zebrafish.

Early life exposure to F-53B induces neurobehavioral changes in developing children and disturbs dopamine-dependent synaptic signaling in weaning mice

Human exposure to F-53B in China and the evaluation of its potential toxicity: An overview

Transcriptomics integrated with metabolomics reveals perfluorobutane sulfonate (PFBS) exposure effect during pregnancy and lactation on lipid metabolism in rat offspring

Metabolic perturbations in pregnant rats exposed to low-dose perfluorooctanesulfonic acid: An integrated multi-omics analysis

Exposure to a PFOA, PFOS and PFHxS Mixture during Gestation and Lactation Alters the Liver Proteome in Offspring of CD-1 Mice

Perinatal exposure to perfluorooctane sulfonate and the risk of hepatic inflammation in rat offspring: Perturbation of gut-liver crosstalk

Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS)